Anticoagulants prevent clotting of blood and the growth of existing blood clots in blood vessels. In recent years, the development of methods for the prevention, and pharmacological and surgical treatment of thrombosis have improved considerably. The LMWHs are being used in the treatment of antithrombotic diseases for the past two decades. Owing to the structural complexity of anticoagulants and the presence of impurities, their structural characterization requires advanced analytical techniques.
The market is expected to grow from US$ 3,658.27 million in 2021 to US$ 5,733.96 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028.
The LMWH exhibits anticoagulant properties such as anti-tumor, anti-inflammatory, and anti-proliferative effects, which are useful in the treatment of pathologies such as nephrotic syndrome and Alzheimer's disease. The patents of LMWH's have now expired. However, the Low Molecular Weight Heparin Market potential for LMWH is growing due to the increasing use in several Western European and emerging countries owing to its uses, such as thromboprophylaxis, venous thromboembolism (VTE), and anticoagulation treatment during pregnancy. As a result, pharmaceutical companies in many countries are focused on producing generic LMWHs.
Enoxaparin is the world's best-selling LMWH. According to Hospital Pharmacy Europe, as of November 2016, several pharmaceutical companies were producing copies of enoxaparin in Argentina, Brazil, Chile, Colombia, Egypt, Ecuador, Georgia, India, Morocco, Myanmar, Peru, the Philippines, South Korea, Tunisia, Turkey, the US, and Venezuela. Pharmaceutical companies from these countries are also conducting various research and development activities to manufacture enoxaparin biosimilar. This further leads to intense competition in the LMWH market. Pharmaceutical companies either produced biosimilars or renamed the generic versions of the branded LMWH. In particular, copies of enoxaparin are available mainly in North and Latin America, and Asian countries. Regulators have developed specific requirements for the approval of the LMWH biosimilar in Australia and Europe.
Get Sample Copy with Complete TOC and Figures Graphs @ https://www.theinsightpartners.com/sample/TIPRE00026174/
About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.
Contact Us:
Call: +1-646-491-9876
Email: [email protected]
